Sandip P. Patel, MD, discusses how AI can be used to improve clinical trial design and accrual.
Vol.27/No.3
Ryan D. Chow, MD, PhD, Ronac Mamtani, MD, MSCE, and Ramy Sedhom, MD, spotlight a real-world analysis of upfront enfortumab vedotin dose reduction in bladder cancer.
Maurie Markman, MD, discusses the role of the individual vs the multidisciplinary team in cancer care.
The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.
The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.
Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.
In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5